A very exciting week, and important milestone, for the development of #Deflexifol™ as a promising new #therapy for the treatment of #paediatric ependymoma and other #brain tumours. #oncology #drugdevelopment #science #CancerResearch #investors anzchog.org/dartstudyopen/

FivepHusion have reached a significant milestone in its Deflexifol™ development with the first patient commencing treatment in its clinical trial 💉🩺 FivepHusion #Oncology #DrugDevelopment #Science #CancerResearch #Investing buff.ly/459DXvh

FivepHusion's CEO Christian Toouli discusses its corporate strategies and focus for the next 6/12 months 💊👨‍⚕️ FivepHusion #DrugDevelopment #Pharmaceutical #BioTech

Great to chat with Rebecca Marsh and The Market Bull - Daily Stock News about our cancer drug #Deflexifol, 2023 partnering deals with Pfizer CentreOne, Syneos Health, TreeHill Partners & Allarity Therapeutics and future plans. #biotech #Invest

FivepHusion's CEO Christian Toouli discusses the end of 2023 and plans for the next 6 months 💊 FivepHusion #Investing #pharmaceutical #biotechnology #drugdevelopment

2024 is expected to be an exciting year as we accelerate development of #Deflexifol as an optimised therapeutic for millions of adults and children with #cancer. #oncology #biotech

Thanks Tylah and The Market Bull - Daily Stock News for this editorial highlighting the promising signs of a #biotech recovery in 2024. #investor #biotechnology #ASX #PharmaceuticalsBiotech

Fantastic news!!!!!! Amazingly, my latest MRI brain scan shows no recurrence 10 months since my #glioblastoma presented with a seizure in #Poland. Median time to recurrence is 6 months. I’m extremely hopeful that the novel #neoadjuvant combination #immunotherapy I’ve had &

ACW’s CEO Dr Steve Gourlay is presenting today as one of the emerging leaders in the Small and Mid-Cap sector. Register for the conference here asx.arinex.one

Dose 8 (of 10) personalised anticancer vaccine administered last week as experimental treatment for my #glioblastoma. Sore arm for a couple of days but otherwise feeling good. Thanks Professor Georgina Long AO (Bluesky @gvlongphdmd), @mariag20057502 & Melanoma Institute Australia team for organising & delivering! I hope everyone

Enrolment completed in XanaCIDD ph 2a cognition & depression trial Full clinical trial enrolment now complete! Our XanaCIDD ph 2a trial of 167 patients with cognitive impairment in major depressive disorder is anticipated to read out in early Q3 this year ow.ly/EHzh50RkNmp

On Monday, I had further experimental treatment for my “brain cancer” #glioblastoma. This was delayed because there had been concerns about some of my blood test results. As a consequence, until recently, I hadn’t been exercising. But I am continuing to feel well. Thank you

Actinogen CMO, Dr Dana Hilt and guests explore the unique properties of Xanamem for the potential treatment of cognitive impairment in multiple diseases. Forum details: 3pm AEST 23 May 2024 Event registration details contained in the announcement. ow.ly/ACZ050RF4Qh

Wonderful news!

Actinogen (ASX:ACW) publishes peer-reviewed paper summarising positive Xanamem phase 2a biomarker trial in 100th volume of the highly respected Journal of Alzheimer's Disease:m ow.ly/aicF50SpH9Y

Attached is an article by Dr Tim Boreham published in the Biotech Daily discussing the history of Actinogen and its potential impact on patients suffering from cognitive impairment, depression and Alzheimer's disease. biotechdaily.com.au/wp/wp-content/… #$ACW

ACW is excited to announce the results from the recent phase 2a XanaCIDD trial which show a clinically and statistically significant improvement in depression. See here for announcement. wcsecure.weblink.com.au/pdf/ACW/028374… $ACW

ACW CEO Steven Gourlay sat down with Sonia Madigan from Market Online to discuss the importance of the XanaCIDD trial results and the potential impact of Xanamem on depression treatment. He also touched on next steps. themarketonline.com.au/actinogen-medi… $ACW

$ACW CEO & CMO presenting at the Sachs Annual Neuroscience Forum in San Francisco (SFO) today. They are joined in SFO by the CFO & CCO, and the team will go on to participate in industry meetings associated with the Annual JP Morgan Healthcare Conference this week.

Missed the $ACW Clinical Trials Science Forum? No problem! A recording is available. Learn about the latest advancements in Alzheimer's trials & $ACWs commercialization strategies for Xanamem & watch a new video explaining its unique mechanism of action youtu.be/QyfiLsSYQVg